c-Jun N-Terminal Kinase Inhibitors as Potential Leads for New Therapeutics for Alzheimer’s Diseases

Alzheimer’s Disease (AD) is becoming more prevalent as the population lives longer. For individuals over 60 years of age, the prevalence of AD is estimated at 40.19% across the world. Regarding the cognitive decline caused by the disease, mitogen-activated protein kinases (MAPK) pathways such as the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hepp Rehfeldt, Stephanie Cristine, Majolo, Fernanda, Goettert, Márcia Inês, Laufer, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765872/
https://www.ncbi.nlm.nih.gov/pubmed/33352989
http://dx.doi.org/10.3390/ijms21249677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7765872/
https://www.ncbi.nlm.nih.gov/pubmed/33352989
http://dx.doi.org/10.3390/ijms21249677

Ejemplares similares